Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | EIF4E | P06730 | 17/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6416284 | 1.00 | MGAM (0.46) | MGAMGAASIMGAM2EIF4E | |
| SCHEMBL829974 | 0.78 | MGAM (0.51) | MGAMGAASIMGAM2EIF4E | |
| SCHEMBL6416859 | 0.76 | ALDH1A1 (0.42) | GAAALDH1A1TDP1 | |
| SCHEMBL6416853 | 0.76 | ALDH1A1 (0.42) | GAAALDH1A1TDP1 | |
| SCHEMBL9832354 | 0.75 | MGAM (0.59) | MGAMGAASIMGAM2EIF4E | |
| SCHEMBL6185761 | 0.74 | ACHE (0.56) | EIF4E | |
| SCHEMBL1208143 | 0.72 | EIF4E (0.70) | EIF4EALDH1A1TDP1 | |
| SCHEMBL6225006 | 0.71 | KDM4E (0.52) | GAAEIF4EALDH1A1 | |
| SCHEMBL6225000 | 0.71 | KDM4E (0.52) | GAAEIF4EALDH1A1 | |
| SCHEMBL6414430 | 0.71 | MGAM (0.45) | MGAMGAASIMGAM2EIF4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | CHRM3, CHRM2, CHRM5 | MGAM 2067/4885GAA 4513/4885SI 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.